Clinical trials update from the European society of cardiology congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY

Cardiovascular Drugs and Therapy

Volumn 21, Issue 6, 2007, Pages 459-465

  Recio Mayoral, A ^a   Kaski, J C ^a   McMurray, J J V ^b   Horowitz, J ^c   Van Veldhuisen, D J ^d   Remme, W J ^e  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

ACUITY; ALOFT; ARISE; CARESS in MI; European Society of Cardiology; EVEREST; FINESSE; Prague 8; PROSPECT; Randomised controlled trials

Indexed keywords

ABCIXIMAB; ALISKIREN; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIRULOG; RETEPLASE; TOLVAPTAN;

ANGIOGRAPHY; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DEATH; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERNATREMIA; INFLAMMATION; ISCHEMIA; LOADING DRUG DOSE; MEDICAL SOCIETY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPERFUSION; SIDE EFFECT; ST SEGMENT ELEVATION; STROKE; THIRST; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

ACUTE CORONARY SYNDROME; AMIDES; ANTIBODIES, MONOCLONAL; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; ELECTROCARDIOGRAPHY; EUROPE; FUMARATES; HEART DISEASES; HEART FAILURE; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PROBUCOL; RECOMBINANT PROTEINS; TICLOPIDINE;

EID: 36849012197     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6069-4     Document Type: Conference Paper

References (15)

1. Yu CM, Abraham WT, Bax J, et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design. Am Heart J. 2005;149:600-5.
2. Gheorghiade M, Gattis WA, O' Connor CM, et al. Effects of tolvaptan, a vasopressin antagoist, in patients hospitalised with worsening heart failure: a randomised controlled trial. JAMA. 2004;291:1963-71.
3. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomised, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-9.
4. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomised, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST). J Card Fail. 2005;11:260-9.
5. Konstam MA, Burnett JC, Gheorghiade M, et al. Effects of oral tolvaptan in patients hospitalised for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-31.
6. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalised for heart failure. The EVEREST clinical status trial. JAMA. 2007;297:1332-43.
7. Serebruany VL, Malinin A, Eisert C, Ong S. AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. Expert Rev Cardiovasc Ther. 2007;5:635-41.
8. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. Am Heart J. 2004;147:E16.
9. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of retreatment platelet reactivity. Circulation. 2003;107:2908-13.
10. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-7.
11. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28:1598-660.
12. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-74.
13. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-63.
14. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-75.
15. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-16.